Gurusamy Umamaheswaran
Overview
Explore the profile of Gurusamy Umamaheswaran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Umamaheswaran G, Kadambari D, Muthuvel S, Kumar N, Dubashi B, Aibor Dkhar S, et al.
PLoS One
. 2021 Mar;
16(3):e0247989.
PMID: 33760860
Letrozole, an aromatase inhibitor (AI), is the first-line adjuvant drug for treating hormone receptor-positive (HR+) breast cancer in postmenopausal women. However, harmful adverse events (AEs) and significant differences in drug...
2.
Umamaheswaran G, Kadambari D, Muthuvel S, Kalaivani S, Devi J, Damodaran S, et al.
Breast Cancer Res Treat
. 2020 May;
182(1):147-158.
PMID: 32385792
Purpose: Musculoskeletal adverse events (MS-AEs) and vasomotor symptoms (VMSs) are the major side-effects of newer generation non-steroidal aromatase inhibitor (AI), letrozole. Single-nucleotide polymorphisms (SNPs) in CYP19A1 gene coding for the...
3.
Pal G, Adithan C, Umamaheswaran G, Pal P, Nanda N, Indumathy J, et al.
J Am Soc Hypertens
. 2016 Oct;
10(11):865-872.
PMID: 27697448
Though endothelial nitric oxide synthase (eNOS) gene polymorphism is documented in the causation of hypertension, its role in prehypertension has not been investigated. The present study was conducted in 172...
4.
Arun Kumar A, Suresh Kumar S, Umamaheswaran G, Kesavan R, Balachandar J, Adithan C
Pharmacol Rep
. 2015 Jan;
67(1):97-101.
PMID: 25560582
Background: Cardiovascular diseases (CVDs) are the major cause of mortality and morbidity worldwide. Myocardial infarction (MI) is a complex multi-factorial, polygenic disorder arising from an interaction between genetic makeup of...
5.
Srinivasa Rao K, Paul A, Arun Kumar A, Umamaheswaran G, Dubashi B, Gunaseelan K, et al.
Biomark Cancer
. 2014 Dec;
6:29-35.
PMID: 25520562
Various DNA repair pathways protect the structural and chemical integrity of the human genome from environmental and endogenous threats. Polymorphisms of genes encoding the proteins involved in DNA repair have...
6.
Umamaheswaran G, Praveen R, Damodaran S, Das A, Adithan C
Clin Exp Med
. 2014 Dec;
15(4):511-7.
PMID: 25492374
Metformin is an oral antidiabetic drug, commonly used for treating type 2 diabetes mellitus (T2DM) patients. It is transported into the hepatocytes by polyspecific organic cation transporter 1, which is...
7.
Umamaheswaran G, Kadambari D, Arun Kumar A, Revathy M, Anjana R, Adithan C, et al.
Environ Toxicol Pharmacol
. 2014 Dec;
39(1):102-13.
PMID: 25481307
Aromatase inhibitors (AIs) are anti-neoplastic drugs widely used for the treatment of endocrine responsive breast carcinoma in postmenopausal women. Drug disposition, efficacy and tolerability of these agents are influenced by...
8.
Srinivasa Rao K, Sureshkumar S, Umamaheswaran G, Paul A, Dubashi B, Gunaseelan K, et al.
Environ Toxicol Pharmacol
. 2014 Aug;
38(2):480-8.
PMID: 25155628
DNA repair genes are crucial in maintaining the integrity of the whole genome. Single nucleotide polymorphisms (SNPs) in DNA repair genes have been attributed to the development of various cancers....
9.
Priyadharsini R, Shewade D, Subraja K, Ravindra B, Umamaheswaran G, Aibor Dkhar S, et al.
Mol Biol Rep
. 2014 Aug;
41(11):7265-71.
PMID: 25112801
Clopidogrel is an antiplatelet drug. It is used for the treatment as well as for the prophylaxis of coronary artery disease. Clopidogrel resistance is an emerging problem in clinical settings....
10.
Umamaheswaran G, Aibor Dkhar S, Arun Kumar A, Srinivasa R, Kadambari D, Adithan C
Bioimpacts
. 2014 Jul;
4(2):95-100.
PMID: 25035853
Introduction: Decline in circulating estrogen levels causes lessening of bone mass accompanied with musculoskeletal pain, which is the primary cause of treatment discontinuation in patients taking aromatase inhibitors. Evidence from...